Check out the fascinating array of topics to be covered during 2023 NACLC satellite CME symposia!
The Basics of Pain Management for Patients With Cancer from Diagnosis to Palliative Care – Thoracic Cancer Edition
Friday, December 1, Noon-1 p.m.: This live symposium focuses on the challenges of managing thoracic cancer pain using a didactic, interactive case-based format. Patient advocates will join the discussion to offer a patient perspective on effective cancer pain management.
Matching Treatment to Patient With EGFR-Mutant Lung Cancer: Mutation Subtypes, Co-Mutations, & Managing Resistance
Saturday, December 2, Noon-1 p.m.: This hybrid educational program highlights and addresses key questions for patients with EGFR-mutated non-small cell lung cancer. Different treatment settings will be showcased through a patient case, followed by panel discussion focusing on challenges that emerge for these patients, as well as actionable solutions.
How CEACAM5 Expression Can Be Measured & Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
Saturday, December 2, 7- 8:30 p.m.: Despite therapeutic advances in immunotherapy and targeted therapy for the treatment of non-small–cell lung cancer (NSCLC), patients still experience disease progression after multiple lines of therapy, stressing the need for new therapeutic mechanisms of action. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is an important antigen that is overexpressed on approximately 20% to 30% of all NSLC adenocarcinomas and has been found to stimulate the progression of disease through cell proliferation and migration. Promising initial evidence demonstrates the potential of targeting CEACAM5 to provide additional therapeutic options for patients with lung cancer, and several ongoing clinical trials are evaluating CEACAM5-targeting agents across different settings in NSCLC. Renowned experts will discuss the clinical rationale for targeting CEACAM5, explore how strategies to test for CEACAM5 fit into larger testing paradigms in NSCLC, and review ongoing research efforts to develop antibody-drug conjugates—including novel CEACAM5-directed therapies—for the treatment of advanced NSCLC.
Harnessing the Power of the Latest Clinical & Research Advances in SCLC: How to Accelerate Progress & Improve Patient Outcomes With Current and Emerging Therapies
Sunday, December 3, 7- 8 a.m.: Advances in the treatment of small cell lung cancer (SCLC) include chemo-immunotherapy as a first-line option for extensive-stage SCLC (ES-SCLC), lurbinectedin (transcription inhibitor) as a second-line therapy, and trilaciclib as a myeloprotective agent. These therapies have become guideline-recommended standards of care in SCLC, providing hope for patients. Ongoing clinical trials are evaluating existing therapies in different settings and combinations, as well as exploring a range of novel therapies and rational combinations with different mechanisms of action. To ensure optimal care, oncologists and other healthcare professionals involved in SCLC treatment must stay up to date with the evolving standards of care, collaborate with multidisciplinary teams, and integrate the latest therapies into clinical practice. It is also crucial that clinicians are aware of emerging and investigational therapy options, allowing prompt access for patients through clinical trials. However, our research indicates healthcare and practice gaps persist in SCLC, partly due to the nature of the disease, the pace of scientific advancements, and their translation into practice. Addressing these gaps requires well-designed educational programs to improve the knowledge, skills, and competence of oncology and multidisciplinary professionals, ensuring that all patients with SCLC can benefit from the latest therapeutic advances.
Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer
Sunday, December 3, 7- 8 a.m.: Antibody–drug conjugates (ADCs) are an exciting new class of therapies that selectively deliver cytotoxic payloads to cancer cells, representing the next frontier in precision lung cancer care. The promise of these agents is finally transitioning from research settings to real-world clinical practice, as exemplified by the first approved HER2-targeting ADC for HER2-mutant NSCLC. In light of this first step in the ADC revolution in lung cancer, various potent ADCs targeting HER3, TROP2, B7-H3, and many others are being investigated, and they are showing impressive activity in different settings and patient populations in NSCLC and SCLC. As ADCs continue to demonstrate the potential to broadly expand into community practice, how do we realize the promise of ADCs for improving outcomes for appropriate patients with lung cancer? This educational symposium will leverage competitive learning in the form of quiz-based challenges, related mini-lectures, and open discussions to expand understanding of the growing arsenal of ADCs as well as potential implications for practice and outcomes for patients with lung cancer. For more information or to register, visit www.peerview.com/chicagoADC-Live
For more conference information, visit 2023 NACLC. Check back here often for conference-related NSCLC abstracts, updates, articles and more!
Create Post
Twitter/X Preview
Logout